Vicente Valentí

952 total citations
19 papers, 609 citations indexed

About

Vicente Valentí is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vicente Valentí has authored 19 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Otorhinolaryngology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vicente Valentí's work include Head and Neck Cancer Studies (5 papers), Cancer Diagnosis and Treatment (3 papers) and Neutropenia and Cancer Infections (3 papers). Vicente Valentí is often cited by papers focused on Head and Neck Cancer Studies (5 papers), Cancer Diagnosis and Treatment (3 papers) and Neutropenia and Cancer Infections (3 papers). Vicente Valentí collaborates with scholars based in Spain, United States and Italy. Vicente Valentí's co-authors include Antonio López–Pousa, H. Cortés-Funes, Juan Luis Gomez Marti, Cinta Pallarés, Joan Carles, Ricardo Hitt, C. Chaib, Miguel A. Sánchez, Antonio Antón and Dolores Isla and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Vicente Valentí

19 papers receiving 598 citations

Peers

Countries citing papers authored by Vicente Valentí

Since Specialization

Citations

This map shows the geographic impact of Vicente Valentí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicente Valentí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicente Valentí more than expected).

Fields of papers citing papers by Vicente Valentí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicente Valentí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicente Valentí. The network helps show where Vicente Valentí may publish in the future.

Co-authorship network of co-authors of Vicente Valentí

This figure shows the co-authorship network connecting the top 25 collaborators of Vicente Valentí. A scholar is included among the top collaborators of Vicente Valentí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicente Valentí. Vicente Valentí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Variation of Plasma Damage-Associated Molecular Patterns in Patients with Advanced Solid Tumors after Standard of Care Systemic Treatment 2023 ·Cancer Investigation ·Vicente Valentí, Lluís Capdevila, Isabel Ruíz-Camps, (unknown), Joan R. Badia, (unknown), (unknown), C. Martin Perez, (unknown), (unknown), Carlos Alonso‐Villaverde	1
2	Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors 2022 ·Neuroendocrinology ·Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, (unknown), Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar	22
3	Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial 2022 ·Annals of Oncology ·Paula Jiménez‐Fonseca, Ramón Salazar, Vicente Valentí, Pavlos Msaouel, Alberto Carmona‐Bayonas	15
4	LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206) 2022 ·Annals of Oncology ·Ramón Salazar, (unknown), Merete Krogh, Àlex Teulé, (unknown), Heinz‐Josef Klümpen, Birgit Cremer, Isabel Sevilla, Bengt O. Eriksson, (unknown), J-P. Metges, N.S. Reed, J. Schrader, (unknown), Vicente Valentí, Jorge Hernando, (unknown), (unknown), Carlo Carnaghi, Jaume Capdevila	21
5	Damage-associated molecular patterns (DAMPS) in patients with advanced cancer undergoing systemic treatment. 2022 ·Journal of Clinical Oncology ·Vicente Valentí, Lluís Capdevila, Isabel Ruíz-Camps, Joan R. Badia, (unknown), (unknown), (unknown), C. Martin Perez, (unknown), (unknown), Carlos Alonso	1
6	Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment 2021 ·Clinical & Translational Oncology ·Alicia Lozano, J. Marruecos, (unknown), Núria Farré, Jaime Gómez‐Millán, (unknown), (unknown), (unknown), (unknown), (unknown), J. Giralt, Germaine Escames, Vicente Valentí, P. Grima, (unknown), (unknown), Ricard Mesı́a	28
7	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit 2021 ·Cancer Investigation ·Vicente Valentí, Paula Jiménez‐Fonseca, Pavlos Msaouel, Ramón Salazar, Alberto Carmona‐Bayonas	4
8	Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer 2019 ·Clinical & Translational Oncology ·Vicente Valentí, Francisco Javier Ramos, (unknown), (unknown), Isabel Ruíz-Camps, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ramón Salazar	13
9	PD-029 Phase II trial: melatonin oral gel for prevention of mucositis in oropharynx and oral cavity tumors 2019 ·Radiotherapy and Oncology ·(unknown), J. Marruecos, Jordi Rubió‐Casadevall, (unknown), Antonio López–Pousa, Jaime Gómez‐Millán, (unknown), R. Morera, (unknown), (unknown), Ricard Mesı́a, (unknown), (unknown), (unknown), (unknown), Vicente Valentí, (unknown), P. Grima, (unknown), (unknown)	1
10	Phase II trial of high-dose melatonin oral gel for the prevention and treatment of oral mucositis in H&N cancer patients undergoing chemoradiation (MUCOMEL). 2018 ·Journal of Clinical Oncology ·Alicia Lozano, J. Marruecos, Jordi Rubió‐Casadevall, Núria Farré, Antonio López–Pousa, J. Giralt, (unknown), Beatriz Cirauqui, (unknown), (unknown), (unknown), Jaime Gómez‐Millán, (unknown), (unknown), (unknown), P. Grima, Vicente Valentí, (unknown), (unknown), Ricard Mesı́a, (unknown)	9
11	Expression of Sonic Hedgehog and Smoothened in Metastatic Colorectal Cancer 2014 ·Annals of Oncology ·Vicente Valentí, (unknown), (unknown), (unknown), (unknown), (unknown)	1
12	Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study) 2011 ·Clinical & Translational Oncology ·Agustí Barnadas, Ricard Mesı́a, Margarita Majem, (unknown), Antonio López–Pousa, (unknown), Mireia Margelí Vila, Vicente Valentí, Lluís Anglada, (unknown), (unknown)	3
13	A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours 2006 ·European Journal of Cancer ·Miguel Izquierdo, Margarita García, (unknown), (unknown), Vicente Valentí, Matilde Navarro, Miguel Gil‐Gil, Felipe Cardenal, Ricard Mesı́a, (unknown), Ramón Salazar, Josep Ramón Germà-Lluch	12
14	RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients 2005 ·Annals of Oncology ·Laura Mercatali, Vicente Valentí, Daniele Calistri, Sebastiano Calpona, Giovanni Rosti, Secondo Folli, Michele Gaudio, Giovanni Luca Frassineti, D. Amadori, Emanuela Flamini	26
15	Radiation-Induced Mandibular Osteogenic Sarcoma: Report of a Case and Review of the Literature 2005 ·Journal of Craniofacial Surgery ·Vicente Valentí, Antonio López–Pousa, Yolanda González, Núria Farré	7
16	Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer 2005 ·Journal of Clinical Oncology ·Ricardo Hitt, Antonio López–Pousa, Javier Martínez‐Trufero, (unknown), Joan Carles, (unknown), Dolores Isla, (unknown), Juan Luis Gomez Marti, Francisco S. N. Lobo, (unknown), Vicente Valentí, Joaquín Belón, Miguel A. Sánchez, C. Chaib, Cinta Pallarés, Antonio Antón, Andrés Cervantes, Luis Paz‐Ares, H. Cortés-Funes	319
17	Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial 2000 ·Journal of Clinical Oncology ·Carlos Gómez-Martín, (unknown), Javier Hornedo, Sofía Perea, Carlos Lumbreras, Vicente Valentí, Alberto Arcediano, (unknown), Ramón Salazar, H. Cortés-Funes, Manuel Hidalgo	15
18	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS) 1998 ·Annals of Oncology ·J. Buesa, Antonio López–Pousa, Javier Martín‐Broto, A. Antón, Javier García del Muro, J Bellmunt, (unknown), Vicente Valentí, P. Escudero, (unknown), Antonio Casado, Andrés Poveda	50
19	Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation 1998 ·Bone Marrow Transplantation ·Ramón Salazar, C. Solà, Pablo Maroto, Josep Tabernero, Joan Brunet, (unknown), Vicente Valentí, (unknown), B. Ojeda, Luis Mendoza, (unknown), J. Montesinos, (unknown)	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact